SDC1 and endothelial dysfunction: In mice treated with S961 for 2 weeks, only few among biomarkers of endothelial dysfunction (Figure 3) displayed significant changes in plasma concentration, including the biomarker of glycocalyx disruption (SDC-1, but not ESM-1), the biomarker of endothelial permeability (sTie-2) with no apparent effect on other biomarkers of endothelial permeability (Angpt-1, Angpt-2, sFLT-1).